In a first conference of the Joint Sectoral Group (JSG, a specialized committee established under the Committee on Trade in Goods of CETA protocol) on pharmaceuticals, further arrangements were discussed. Possible extensions of the scope would be to include GMP inspections of active substance manufacturers and inspections conducted in third countries.

Following a recently expanded MRA with Japan and a MRA with the US FDA, this would be another move to make better use of inspection resources by reducing duplicate inspections in each other’s territory and eventually in third countries.

Source:

European Commission